onatasertib

Onatasertib is an orally available, selective dual inhibitor of the mammalian target of rapamycin (mTOR) kinase complexes mTORC1 and mTORC2. It is a small molecule antineoplastic agent developed for the treatment of various cancers. By inhibiting both mTORC1 and mTORC2, onatasertib disrupts key signaling pathways involved in tumor cell growth, proliferation, and survival, leading to induction of apoptosis and decreased tumor cell proliferation. Preclinical studies have shown that it can also disrupt mitochondrial function and induce reactive oxygen species production. Onatasertib has been investigated in clinical trials for multiple myeloma, non-Hodgkin's lymphoma (including diffuse large B-cell lymphoma), solid tumors (including liver cancer and non-small cell lung cancer), glioblastoma multiforme, hepatocellular carcinoma, cervical cancer, nasopharyngeal carcinoma, ovarian carcinoma, among others[1][2][3][4][5][6].

Brand names

onatasertib

Other names

onatasertibATG 008ATG008ATG-008CC-223CC223CC 223